Young Blood Factor Review 2026: Cardiac Safety and Anti-Aging Claims

Updated October 2, 2026

This article is for informational and educational purposes only and does not constitute medical advice. Consult your physician before starting any supplement, particularly if you have a cardiovascular condition or take prescription medications. UTCardiothoracicSurgery.com Editorial Team | January 2026.

This article may contain affiliate links. If you purchase through a link in this article, a commission may be earned at no additional cost to you. This does not affect the objectivity of the information presented.

FTC disclosure required by 16 C.F.R. Part 255.

Cardiac Safety Summary: Young Blood Factor

Product Type: Anti-aging dietary supplement (proprietary blend)
Key Ingredients: Not fully disclosed; marketed as proprietary formula
Price Range: Not verified
Refund Policy: Not disclosed
Cardiac Drug Interactions: Potential concerns with anticoagulants and blood pressure medications due to undisclosed ingredients; full safety profile cannot be assessed without complete ingredient transparency
Quick Answer: Young Blood Factor is marketed as an anti-aging supplement but relies heavily on proprietary blending that obscures individual ingredient amounts. Cardiac patients cannot accurately assess drug interaction risk without full label transparency. This lack of disclosure is a significant red flag for individuals on warfarin, beta-blockers, or other cardiovascular medications.

What Makes This Review Different: Why Cardiac Patients Need Ingredient Transparency

Most wellness reviews evaluate Young Blood Factor through a general vitality and anti-aging lens, focusing on user testimonials and marketing claims about cellular rejuvenation. This review takes a fundamentally different approach: we evaluate the product through the cardiac safety lens that defines UTCardiothoracicSurgery.com. For patients managing hypertension, atrial fibrillation, heart failure, or post-cardiac event recovery, a supplement's ingredients—and their doses—directly influence safety with prescription medications.

The critical question other reviewers miss is this: If a supplement's formula is proprietary and undisclosed, how can a cardiologist assess the risk of drug interaction? Young Blood Factor presents a particular challenge because its marketing emphasizes “cellular regeneration” and “blood rejuvenation,” language that suggests cardiovascular relevance but lacks scientific specificity. Cardiac patients deserve to know exactly what they are taking and in what amounts before adding it to a medication regimen that may include warfarin, metoprolol, lisinopril, or atorvastatin.

What Young Blood Factor Is: Verified Product Summary

According to available information, Young Blood Factor is marketed as an anti-aging dietary supplement designed to support cellular renewal and vitality. The product is presented as a proprietary formula, meaning the manufacturer combines multiple ingredients into a blend without publicly disclosing individual amounts. Young Blood Factor is typically available in capsule or powder form, though exact serving sizes and format specifics are not independently verified through this review.

The suggested use, according to marketing materials, centers on daily consumption to support what the brand describes as “rejuvenation” and “age-reversal mechanisms.” However, the supplement facts panel—which would list each ingredient and its amount in milligrams—has not been made fully available for this analysis. This absence of transparent labeling is itself a significant finding and represents a departure from industry best practices, particularly for a product marketed to adults who may have age-related cardiovascular conditions.

The Label vs. Marketing Analysis: Proprietary Blend Opacity

Young Blood Factor's marketing creates a substantial disconnect between claims and verifiable ingredient information. The brand's advertising emphasizes “blood rejuvenation,” “cellular regeneration,” and “youthful vitality restoration”—language that strongly implies cardiovascular and metabolic benefits. However, the actual supplement facts panel does not disclose individual ingredient amounts, instead grouping components into a proprietary blend.

This practice is legal under FDA regulation but represents a transparency gap that is particularly problematic for cardiac patients. Marketing materials suggest the formula includes anti-aging and circulation-supporting ingredients, but without knowing the specific doses, healthcare providers cannot evaluate whether those ingredients pose interaction risks. For comparison, evidence-based supplements used by cardiac patients—such as CoQ10 or magnesium supplements—typically disclose exact doses (e.g., “CoQ10 300 mg per capsule”).

Young Blood Factor's refusal to provide this level of transparency suggests either that doses are subtherapeutic (too low to be clinically relevant) or that the manufacturer prefers to limit independent scrutiny. Either scenario raises concern for informed cardiac patients. The absence of any cardiac safety disclaimer on marketing materials is notable, given that the product's name references “blood.”

Young Blood Factor Ingredient Evidence and Dose Analysis

Because Young Blood Factor's complete ingredient list and doses are not publicly available, this section is significantly limited—a problem in itself. Based on available information and industry context for anti-aging supplements, proprietary formulas of this type often include ingredients such as resveratrol, NAD+ precursors, amino acids, plant extracts, or peptide complexes. If Young Blood Factor includes resveratrol—a polyphenol from grape skin studied for aging-related benefits—the clinical evidence is mixed.

A 2019 systematic review in Nutrients found that while resveratrol shows promise in cell cultures, human trial evidence remains limited, and doses used in research (typically 500–2,000 mg) often exceed supplement amounts. NAD+ boosters like NMN or NR have gained popularity in anti-aging circles, but human clinical evidence for dose-dependent effects remains preliminary. The critical issue is that without knowing Young Blood Factor's doses, this review cannot determine whether amounts align with studied doses or fall below therapeutic thresholds.

For cardiac patients, this uncertainty is unacceptable. If the formula includes stimulating ingredients (e.g., high-dose caffeine or herbal extracts), undisclosed amounts could elevate heart rate or blood pressure in ways that conflict with cardiac medication regimens. The lack of ingredient transparency prevents independent dose-effect analysis and represents a major limitation for safety assessment.

Young Blood Factor Cardiac Safety Profile: Drug Interactions and Missing Transparency

This is the most critical section for readers with cardiovascular conditions. Young Blood Factor's cardiac safety profile cannot be adequately assessed due to incomplete ingredient disclosure. However, the marketing language and product positioning create specific concerns:

Anticoagulant and Antiplatelet Interactions: The product's emphasis on “blood rejuvenation” raises questions about whether it contains ingredients that affect blood clotting. If Young Blood Factor includes high-dose vitamin K, ginger extract, garlic, or other blood-thinning botanicals, it could interact with warfarin (Coumadin) or other anticoagulants by either reducing efficacy or increasing bleeding risk. Patients on warfarin require consistent ingredient profiles and must disclose all supplements to their anticoagulation clinic. A proprietary blend prevents this disclosure.
Blood Pressure and Beta-Blocker Interactions: If the formula includes stimulating ingredients (herbal adaptogens, caffeine, or vasodilators), it could raise blood pressure or heart rate, potentially opposing beta-blockers like metoprolol or carvedilol. Patients on beta-blockers for hypertension, angina, or post-MI management need to know whether a supplement could counteract medication effects.
Statin Interactions: Some anti-aging ingredients (particularly those claiming CoQ10-like effects) may theoretically affect statin metabolism, though the evidence is limited. Without ingredient disclosure, this risk cannot be quantified.
ACE Inhibitor and Potassium Considerations: If Young Blood Factor contains potassium-rich plant extracts or amino acids that raise serum potassium, it could pose a hyperkalemia risk when combined with ACE inhibitors like lisinopril or ramipril.

The fundamental problem is that without a complete, transparent ingredient list with disclosed doses, no cardiologist can accurately counsel a patient on safety. This represents a significant gap in the product's suitability for the cardiac population.

Young Blood Factor User-Reported Outcomes and Review Patterns

User reviews for Young Blood Factor are available on various retail platforms, with reported benefits clustering around perceived improvements in energy, skin appearance, and general vitality. However, most reviews are anecdotal testimonials without baseline health metrics, control comparisons, or verification that improvements resulted from the supplement rather than placebo effect, concurrent lifestyle changes, or natural aging variation. Independent third-party verification of these claims has not been completed for this review.

Cardiac-specific adverse event reports—such as changes in heart rhythm, blood pressure spikes, or bleeding events—are not documented in available public sources, but the absence of reported problems does not confirm safety; it may simply reflect that cardiac patients are underrepresented in the user review base or that adverse events went unreported. For cardiac populations, reliance on user testimonials rather than clinical trial data is insufficient.

Young Blood Factor Pricing and Refund Terms

Specific pricing information and refund policies for Young Blood Factor have not been independently verified through this review. Pricing and availability vary by retailer and region. According to available information, the product is marketed through multiple online channels, but cost-per-serving analysis and money-back commitment terms are not disclosed in accessible sources.

Readers interested in purchasing should contact the manufacturer directly or check the product's official website for current pricing, bulk discounts, and return policies. Pricing is subject to change. Verify current pricing on the manufacturer's official listing.

Buyer Takeaway: Who Should Consider Young Blood Factor and Who Should Avoid It

Young Blood Factor's marketing positions it as an anti-aging solution for adults seeking cellular rejuvenation. However, for cardiac patients—the population most likely to seek anti-aging benefits due to age-related cardiovascular disease—this product presents a transparency and safety assessment problem. The proprietary blend structure means individuals on warfarin, beta-blockers, ACE inhibitors, or other cardiovascular medications cannot confidently determine whether the supplement will interact with their therapy.

This alone warrants caution. The lack of published clinical trials specific to Young Blood Factor, combined with absent ingredient disclosure, means the evidence supporting anti-aging claims remains anecdotal rather than scientific. Cardiac patients and their cardiologists should request a complete supplement facts panel with disclosed doses before considering use.

If the manufacturer declines to provide this information, that refusal itself is a red flag suggesting either subtherapeutic doses (limiting benefit) or reluctance to permit independent safety review. For general wellness seekers without cardiovascular conditions or medications, the product may present lower interaction risk, but even then, the absence of clinical evidence for efficacy limits recommendation. The reviewed evidence does not support marketing claims as superior to established interventions (exercise, Mediterranean diet, sleep, stress management) for aging-related vitality.